PUREVAX Recombinant FeLV

Feline Leukemia Vaccine,

Live Canarypox Vector, rFeLV

rFeLV

SWD

Description

PUREVAX^® Recombinant FeLV contains a non-adjuvanted lyophilized suspension of a recombinant vectored feline leukemia vaccine plus sterile water diluent. A canarypox vector has been modified, using recombinant technology, to produce expression of desired antigens capable of stimulating a protective immune response to feline leukemia. Safety and immunogenicity of this product have been demonstrated by vaccination and challenge tests in susceptible cats.

PUREVAX Recombinant FeLV Indications

PUREVAX^® Recombinant FeLV is recommended for the vaccination of healthy cats 8 weeks of age or older as an aid in the prevention of disease due to feline leukemia virus.

DOSAGE: Aseptically rehydrate the lyophilized vaccine with 1 mL of the accompanying sterile water diluent, and agitate. Administer 1 mL (1 dose) subcutaneously. For primary vaccination, cats should receive two 1-mL dose vaccinations, three weeks apart. Annual revaccination is recommended. Diagnostic testing for FeLV prior to vaccination is recommended.

PRECAUTIONS: Store at 2-8°C (35-46°F). Burn container and all unused contents. Contains gentamicin as a preservative. It is generally recommended to avoid vaccination of pregnant cats. In rare instances, administration of vaccines may cause lethargy, fever, and inflammatory or hypersensitivity types of reactions. Treatment may include antihistamines, anti-inflammatories, and/or epinephrine.

SOLD TO VETERINARIANS ONLY.

For veterinary use only.

Manufactured By: MERIAL, INC., Athens, GA 30601 USA

U.S. Vet. Lic. No. 298

1-888-Merial-1 (1-888-637-4251)

^®PUREVAX is a registered trademark of MERIAL

©2011 Merial. All rights reserved.

CPN: 11111240